Investing.com - Aridis Pharma reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Aridis Pharma announced earnings per share of $-0.470 on revenue of $399K. Analysts polled by Investing.com anticipated EPS of $-0.170 on revenue of $11.2M.
Aridis Pharma shares are down 60% from the beginning of the year , still down 78.80% from its 52 week high of $4.34 set on Tuesday, December 21, 2021.
Aridis Pharma follows other major Healthcare sector earnings this month
Aridis Pharma's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar